Literature DB >> 12798312

Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II.

Doris Stoermer1, Qun Liu, Monicia R Hall, Juliet M Flanary, Ajit G Thomas, Camilo Rojas, Barbara S Slusher, Takashi Tsukamoto.   

Abstract

A series of hydroxamic acids has been prepared as potential inhibitors of glutamate carboxypeptidase II (GCP II). Compounds based on a P1' residue (primed-side inhibitors) were more potent than those based on a P1 group (unprimed-side inhibitors). Inhibitory potency of the primed-side GCP II inhibitors was found to be dependent on the number of methylene units between the hydroxamate group and pentanedioic acid. Succinyl hydroxamic acid derivative, 2-(hydroxycarbamoylmethyl)pentanedioic acid, is the most potent GCP II inhibitor with an IC(50) value of 220nM. The comparison of the results to those of other classes of GCP II inhibitors as well as hydroxamate-based MMP inhibitors provides further insight into the structure-activity relationships of GCP II inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798312     DOI: 10.1016/s0960-894x(03)00407-4

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

2.  Proteomic profiling of metalloprotease activities with cocktails of active-site probes.

Authors:  Stephan A Sieber; Sherry Niessen; Heather S Hoover; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2006-03-26       Impact factor: 15.040

Review 3.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors.

Authors:  Zahra Nikfarjam; Farshid Zargari; Alireza Nowroozi; Omid Bavi
Journal:  Biophys Rev       Date:  2022-01-13

Review 5.  Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects.

Authors:  Marcela Krečmerová; Pavel Majer; Rana Rais; Barbara S Slusher
Journal:  Front Chem       Date:  2022-05-20       Impact factor: 5.545

6.  Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase.

Authors:  Lionel Kuntz; Denis Tritsch; Catherine Grosdemange-Billiard; Andréa Hemmerlin; Audrey Willem; Thomas J Bach; Michel Rohmer
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

7.  Identification and characterization of novel inhibitors of Mammalian aspartyl aminopeptidase.

Authors:  Yuanyuan Chen; Hong Tang; William Seibel; Ruben Papoian; Ki Oh; Xiaoyu Li; Jianye Zhang; Marcin Golczak; Krzysztof Palczewski; Philip D Kiser
Journal:  Mol Pharmacol       Date:  2014-06-09       Impact factor: 4.436

8.  Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.

Authors:  Zora Novakova; Jiri Cerny; Cindy J Choy; Jessie R Nedrow; Joeseph K Choi; Jacek Lubkowski; Clifford E Berkman; Cyril Barinka
Journal:  FEBS J       Date:  2015-11-05       Impact factor: 5.542

9.  Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.

Authors:  Michael Nedelcovych; Ranjeet P Dash; Lukáš Tenora; Sarah C Zimmermann; Alexandra J Gadiano; Caroline Garrett; Jesse Alt; Kristen R Hollinger; Elie Pommier; Andrej Jančařík; Camilo Rojas; Ajit G Thomas; Ying Wu; Krystyna Wozniak; Pavel Majer; Barbara S Slusher; Rana Rais
Journal:  Mol Pharm       Date:  2017-08-31       Impact factor: 5.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.